Skip to content
value.today

Tetherex Pharmaceuticals Corp

🇺🇸 Oklahoma City, Oklahoma, USABiotechnologyFounded 2014
Total raised
$44 M
2 rounds on record
Latest round
$43 M
Feb 2018
First round on record
Feb 2015
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tetherex Pharmaceuticals Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2018$43 MNo. 2$10 to $50 million

Tetherex Pharmaceuticals Corp: Raise no. 2, Feb 2018

Investors in this round

240 investors had bought by the notice of Mar 6, 2018: 240 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$43 M of $50 M offered; $7 M still to sell
Smallest investment taken
$9,988
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Facloner · Executive Officer
  • Jonathan Stocker, Ph.D. · Executive Officer
  • Richard Alvarez · Executive Officer
  • Russell Rother, Ph.D. · Executive Officer, Director
  • Scott Rollins, Ph.D. · Executive Officer, Director
  • David Keiser · Director
  • Philip Jones, M.D. · Director
  • Rodger McEver, M.D. · Director
  • Todd Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount sold Includes $38,446,655 in new funds raised and approximately $4,533,820 in principal and interest under notes that converted into Series B preferred shares at the initial closing.”
  • On the use of proceeds: “Salaries to be paid to executive officers over the next 12 months”

Signed by Douglas A. Branch, Secretary. Source: SEC Form D, newest notice filed Mar 6, 2018. Read the notice at the SEC.

equitySEC
Feb 2015$1 MNo. 1Under $2 million

Tetherex Pharmaceuticals Corp: Raise no. 1, Feb 2015

Investors in this round

14 investors had bought by the notice of Feb 23, 2015: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$5,300
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Facloner · Executive Officer
  • Richard Alvarez · Executive Officer
  • Russell Rother · Executive Officer
  • Scott Rollins, Ph.D. · Executive Officer, Director
  • David Keiser · Director
  • Philip Jones, M.D. · Director
  • Rodger McEver, M.D. · Director
  • Todd Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Douglas A. Branch, Secretary. Source: SEC Form D, newest notice filed Feb 23, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tetherex Pharmaceuticals Corp had no revenue when it filed its newest notice of a funding round (Mar 2018).

    SEC Form D (revenue range) · Mar 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2018

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Tetherex Pharmaceuticals Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 240 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tetherex Pharmaceuticals Corp
NameRoleNamed in
David FaclonerExecutive officerMar 2018
Jonathan Stocker, Ph.D.Executive officerMar 2018
Richard AlvarezExecutive officerMar 2018
Russell Rother, Ph.D.Executive officerMar 2018
Scott Rollins, Ph.D.Executive officerMar 2018
Russell RotherExecutive officerFeb 2015
David KeiserDirectorMar 2018
Philip Jones, M.D.DirectorMar 2018
Rodger McEver, M.D.DirectorMar 2018
Russell Rother, Ph.D.DirectorMar 2018
Scott Rollins, Ph.D.DirectorMar 2018
Todd FoleyDirectorMar 2018